Biogen Idec highlights progress on corporate strategy

Biogen Idec has provided an update on the strong progress it is making in executing its commercial strategy and research programmes during a recent analyst day.

The company highlighted the successful ongoing development of its various multiple sclerosis (MS) drugs, including the oral therapy BG-12, as well as a new treatment that aims to reverse the damage done by the condition.

Over the coming years, Biogen Idec plans to introduce therapies for haemophilia and amytrophic lateral sclerosis, while it has also bolstered its pipeline through various business development deals.

Additionally, the firm will be redoubling efforts to discover new targets, as well as forging new collaborations with leading academic researchers.

Dr George Scangos, chief executive officer of Biogen Idec, said: "I feel good about where Biogen Idec is today and our prospects in 2012 and beyond. We have re-established excellence in our commercial organisation."

Last month, the company conducted a number of initiatives to raise awareness of MS to coincide with the fourth annual World MS Day event.